HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Lowers Price Target to $60

Benzinga Newsdesk www.benzinga.com Negative 62.6%

Neg 62.6% Neu 0% Pos 0%

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and lowers the price target from $67 to $60.